Dendreon’s Reached Orbit… Now Who’s Next?

by Robert Williams, Publisher

When the opening bell rang on Tuesday morning, as the broader market sagged, shares of Dendreon Corp. (Nasdaq: DNDN) sprinted out of the gates, rising by 5.7%.

Unless you live in a cave, you should know about this biotech stock.

Back in April, shares went “parabolic,” blasting 454% higher during the month.

(That’s not a typo. The stock increased almost five-fold over the course of a single month, rendering the S&P 500’s 10% gain over the same period completely insignificant.)

With an impressive move like that, you might think the run is over. But shares will likely head higher still…

You see, Dendreon is blazing a brand new path in biotech. Its prostate cancer drug, Provenge, which it just submitted to the FDA for approval, is the first of its kind. Known as an active immunotherapy, it trains a patient’s immune system to attack deadly cancer cells instead of relying on surgery, radiation treatment, or an injected drug to wipe them out.

In laymen’s terms, Provenge is a cancer vaccine. And the growth for such vaccines is expected to soar by roughly 30% per year through 2012, according to the research firm, RNCOS, Inc. At such a rapid rate, cancer vaccines will account for one-quarter of the global vaccine market.

The good news is that Dendreon isn’t the only player in the space. After all, we’ll need more than one immunotherapy to help combat the 12 million new cancer patients annually. And Dendreon’s success is opening the door for other companies developing immunotherapy treatments that might not otherwise get a chance.

Today, our small and micro-cap specialist Louis Basenese reveals one such company, delivering promising early clinical results, which he believes could ultimately lead to similar profits like those of  investors in Dendreon Corp.

A 454% return or more? That’s a bold claim, no doubt. So check in with Louis to find out how it’s possible.

Ahead of the tape,

Robert Williams

PR: wait… I: wait… L: wait… LD: wait… I: wait… wait… Rank: wait… Traffic: wait… Price: wait… C: wait…

• Dendreon Corp. (Nasdaq: DNDN): Put These Two Promising Biotech Stocks on Your Watch List
• The Next Big Thing in Health Care: How to Profit From Immunotherapy & Regenerative Medicine
• Biotech Stocks: The Market’s Best Bargain Right Now…

Sign Up now and receive this Free report: Collect 122% in the Next 12 Months From Gold's Surge.

The Single Best Investment for 2009

Forget another stimulus package. Or retreating into "safe-havens" like cash and gold. All you need in 2009 is a small exposure to the "secret" White Cap Index.

It's up as much as 171% straight through Wall Street's meltdown. And one of the latest stocks to be added - an Internet-related venture capital company - is up over 100% since its inclusion into the Index.

Just weeks from now, we'll add another White Cap stock to this market-trouncing index. To get a sneak peek, click here for full details.

One Response to “Dendreon’s Reached Orbit… Now Who’s Next?”

1. j delaney Says:
   November 9th, 2009 at 2:09 pm

   How-where can I buy Northwestbiotherapeutics

   Reply

Comments

Check out our selection of daily Investment Research:

We Respect Your Privacy

---

What is Investment U?

Since 1999, Investment U has provided impartial, no-nonsense investment advice on how to build long-lasting wealth.

---

Recent Articles

Platinum Services

The Oxford Club is an exclusive, global network of investors, who collectively participate in the pursuit of prosperity and wealth. The Club is renowned for its market-beating, tried-and-true investment principles.

The White Cap Report exclusively identifies companies, White Caps, which - by being among the earliest to gain traction - have secured dominant positions within untapped, billion-dollar markets.

With an elite trading team at the helm, the Xcelerated Profits Report shows any investor how to "invest like a pro," using high-level, yet easy-to-execute strategies that "xcelerate" profits while minimizing risk.

---